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 Complement is a proteolytic cascade that upon activation plays a key effector role in the 
innate immune system and acts to prime the adaptive immune response. During normal 
homeostatic events, complement is tightly regulated for its roles in immune complex clearance, 
lysis of target cells, opsonization, and recruitment of leukocytes and monocytes to target areas. 
Several endogenous regulators are responsible for the control of complement activation, however 
when dysregulation occurs, aberrant complement activation has been linked to autoimmune, 
proinflammatory, and neurodegenerative diseases, including Alzheimer’s disease. Inhibition of 
the classical complement component C1 may ameliorate hallmarks of autoimmune and 
inflammatory disease.  
 
 
 The serine proteases within the C1 complex, C1r and C1s, are promising therapeutic 
targets for structure-based small-molecule drug development. We investigated the activity of a 
series of small-molecule compounds identified in a large-scale fragment library screen and those 
from a cheminformatics computational docking screen in which hit compounds were predicted to 
bind the C1r or C1s proteases. Using surface plasmon resonance and ELISA-based assays for hit 
validation, we analyzed the binding affinities and the inhibitory IC50’s of several compounds 
predicted to bind and inhibit the activation of C1r or C1s in a dose-dependent manner. In this 
study, we have identified four lead compounds (cmp-1611, cmp-1663, cmp-1696, cmp-1827) 
and their 10 active structural analogues that target and inhibit C1r activation.  
 Given their abilities to bind and inhibit C1r and favorable physicochemical properties, 
our lead compounds may provide a starting point for optimizing affinity and specificity 
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CHAPTER 1: INTRODUCTION 
The complement system is a proteolytic cascade that upon activation plays a key effector 
role in the innate immune system and acts to prime the adaptive immune response. During 
normal homeostatic events, complement is tightly regulated for its roles in immune complex 
clearance, lysis of target cells, opsonization, and recruitment of leukocytes and monocytes to 
target areas. In healthy systems, the balance between activation of complement and its regulation 
maintains a fine line. Despite stringent regulation, dysregulation does occur and is implicated in 
a wide array of host autoimmune, inflammatory, and neurodegenerative diseases. We are 
working on developing small-molecule inhibitors of the initiating proteases, C1r and C1s, of the 
classical complement pathway to halt aberrant activation at the beginning of the cascade using 
both fragment-based drug discovery and cheminformatics. Our data suggest that small-molecule 
inhibitors prevent classical pathway activation and support the further development of C1r- and 
C1s- directed therapeutics in a growing field devoid of initiating protease-specific inhibitors for 
the treatment of classical pathway-mediated diseases. 
1.1  Complement system 
In the late 1800s, immune clearance of microbial pathogens was on the forefront of 
scientific research, and complement made its entrance as simply a “heat labile factor in blood 
capable of killing bacteria” that aided antibody-mediated lysis 1. Due to its helper role in tagging 
antigens and microbes for lysis, it was later termed ‘complement’ 2. Despite its identifying role 
as a key support player in immune defense, we now know that complement is far more involved 
in immune health than simply eliminating microbial pathogens. 
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In addition to “complementing” the innate and adaptive immune response, complement 
can coordinate a number of responses vital to maintaining host homeostasis, such as synapse 
maturation and plasticity, clearance of immune complexes, angiogenesis, mobilization of 
hematopoietic stem-progenitor cells, tissue regeneration, and lipid metabolism 3.The complement 
system is acutely trained to respond to non-self-antigens, cellular debris/irregular aggregates, and 
apoptotic cells versus healthy host cells 4. 
Complement activation occurs through a variety of different mechanisms, and the 
activation target varies between complement components divided between one of three different 
complement pathways: the classical complement pathway (CP), the lectin pathway (LP), or the 
alternative pathway (AP). Initiating events of complement activation are pathway-specific and 
utilize conserved mechanisms 4. 
Under normal homeostatic conditions, the alternative pathway is always active at low 
levels, initiated by a spontaneous hydrolytic process known as “tick-over” (Figure 1). 
Complement component 3 (C3), which is the central complement component of all three 
pathways, spontaneously cleaves its labile thioester bond, introducing a binding site for Factor B, 
followed by cleavage by Factor D. These cleavage events ultimately result in the generation of 
enzymatically active C3 convertase (C3bBb). C3 convertase cleaves C3 to C3b, which can then 
go on to form its own C3 convertase 5. In doing so, complement activates in an exponential 
fashion by serving as its own internal amplification loop while also continuing to progress down 
the pathway to generate the downstream products of the alternative pathway, leading to the 








While the alternative pathway remains active, the lectin pathway and classical pathways 
are initiated by specific targets that signal danger to the host via pathway-specific recognition 
molecules (PRMs), mannose-binding lectin (MBL)/ficolins and C1q, respectively 4. The 
recognition molecules bind the target surface, causing activation of initiating proteases, MASPs 
for lectin pathway or C1r and C1s for classical pathway. The two pathways progress by 
Figure 1. The complement pathways. Complement is activated by three canonical pathways 
known as the classical pathway, lectin pathway, or alternative pathway. Activation of the 
classical complement pathway begins when the pattern recognition protein C1q binds to target 
surfaces resulting in the autoactivation of the zymogen C1r proteases to proteolytically cleave 
and activate C1s within the C1 complex (i.e., C1qC1r2s2). In a similar fashion, the lectin 
pathway is activated by lectin pathway-specific pattern recognition proteins in complex with 
mannose-binding associated serine proteases (MASPs), while the alternative pathway is 
constitutively activated at low levels by a spontaneous hydrolytic event known as ‘tick-over.’ 
Both the classical and lectin pathways converge at the cleavage of C2 and C4 to generate the 
classical/lectin pathway C3 convertases, C4b2b. Alternative pathway activation results in the 
formation of C3 convertases in the form of C3bBb. C3 convertases cleave the central molecule 
of the cascade, C3, into C3a and C3b, resulting in an amplification loop that produces 
increasing quantities of surface bound C3b. At high surface concentrations of C3b, C3 
convertases bind an additional C3b molecule, resulting in a switch of substrate specificity to 
C5. Cleavage of C5 by these C5 convertases (i.e., C4b2bC3b and C3bBbC3b) results in the 
release of the anaphylatoxin C5a and the formation of the pore-like lytic structure called the 




proteolytic cleavage of the same downstream complement components, C4 and C2, to form the 
surface-bound protein complex C4bC2b. C4bC2b is the C3 convertase of the lectin pathway and 
classical pathways. Here, all three pathways converge at the amplification loop for the generation 
of C3b and C3 convertase, amplifying the outcomes of each pathway 6.  
Though having similar structural appearance to C1q, MBL is activated by sugar patterns 
associated with bacteria, viruses, and apoptotic cells, which the lectin pathway recognizes as 
pathogenic 7. C1q, on the other hand, recognizes and binds over 100 structurally diverse and 
distinct ligands, including IgM and hexameric IgG immune complexes 8. Due to its diverse 
recognition ability, the classical complement pathway is regarded as perhaps the most complex 
and integrative of complement systems. 
C1 complex binds a wide range of ligand activators through pattern recognition 
molecules, C1q (Figure 2A). The N-terminal region of C1q forms a cylinder-like collagen stem 
composed of interchain disulfide bridges that stabilize the structure, whereas the C-terminal 
region forms the six globular heads responsible for activator recognition and multivalent 
attachment 8. C1q is in complex with tetrameric C1r and C1s proteases, C1r2s2. C1r and C1s are 
structurally homologous, being made up of the six domains: CUB1-EGF-CUB2-CCP1-CCP2-SP 
(Figure 2B). Each protease is characterized by the inactivated conformation of the catalytic triad, 
a self-inhibitory scissile loop, and cysteine salt bridge within the serine protease domain 9. The 
exact orientation of trypsin-like C1r and C1s within the C1 complex is under debate, creating a 
rift in the theory behind the molecular events precipitating C1r autoactivation. One theory posits 
that the serine protease domains of each protease are condensed within the center of C1 complex, 
beneath the C1q stalks. The binding of C1q to a target substrate induces a conformational change 
in C1q collagen stems and, subsequently, a conformational change in C1r 10. This mechanical 
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stress auto-activates C1r, which then acts upon C1s to induce intramolecular activation, 
converting C1 complex to “activated C1.” The intramolecular rearrangement of the C1r2C1s2 
tetramers shifts the serine protease domains outwards so that they are then accessible as binding 
sites 10. 
The prevailing model for C1r activation places the serine protease domains of both C1r 
and C1s extending beyond the C1q stalks 11. The two C1s molecules centrally dimerize via the 
CUB1-EGF domains, which also serve as the interface for C1r. C1q is bound to the CUB1 and 
CUB2 domains of C1r and the CUB1 domain of C1s. Instead of intramolecular activation, 
classical pathway activators concentrate C1 molecules together in a manner that aligns the 
exposed serine protease domains of C1r to allow for intermolecular C1 activation. If this is true, 
it may also be true that C1r activates neighboring C1s in the same molecule 12. This concept is 
supported by biochemical evidence that lectin pathway activation occurs by proteolytic cleavage 
between MASPs on different pattern recognition molecules, where the role of activation-
inducing glycans is to locally concentrate and orient MASPs for serine protease interaction. This 
process results in complement activation by the ligand-driven juxtaposition of discrete pattern 
recognition complexes 13.  
Upon activation of C1s, activated C1 is then free to cleave target substrates, C4 and C2, 
to generate membrane-bound pathway amplifier, C3 convertase (C4bC2b) 14. The classical 
pathway serine proteases are directly responsible for the cascade progression in the classical 
pathway.  C3 convertases (C3bBb and C4bC2b) switch specificity to C5 upon reaching a high 
concentration to generate C5 convertases (C4b2b3b and C3bBbC3b). Surface-bound C5b binds 
C6, C7, C8β, C8αγ, and C9 consecutively forming MAC 4. As these cleavage events occur, fluid-
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phase complement protein products are also produced and act as opsonins to recruit professional 










(black & violet) 
A 
Figure 2. Structure of C1 complex and C1r monomer. (A) The C1 complex is made up of 
the recognition molecule, C1q, with six globular heads for multivalent attachment, and the 
proteolytic homodimers, C1r2C1s2. Upon C1 fixation to a target site, C1r autoactivates and 
cleaves pro-C1s, yielding enzymatically active C1s with its serine protease domains extending 
beyond the C1q stalks to provide a binding site for its natural substrates C4 and C2 12. (B) The 
C1r monomer is comprised of six domains, starting with the CUB1, EGF, and CUB2 at the N-
terminus and the proteolytically-active CCP2 and the serine protease domains terminating at 
the C-terminus. The CCP2-SP domains can be recombinantly expressed to form stable and 
functionally active truncations 84. 
 
B 
Model of C1r monomer 
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1.2 Complement-mediated disorders 
Complement is primarily derived from the liver to circulate systemically in plasma for 
continuous immune surveillance. However, there are many extrahepatic sources that produce 
complement components locally, such as in immune privileged sites 15. In the brain, complement 
is produced by glia and/or neurons. In Alzheimer’s disease, complement involved in perpetuating 
disease within the brain parenchyma is sourced primarily via locally produced complement 16. 
Circulating plasma-derived complement is speculated to also be able to pass through the 
disrupted blood-brain barrier (BBB) during infection, injury, infarct or inflammation by C2a, 
which may enhance permeability 17.  
Several endogenous regulators are responsible for the control of complement activation, 
but as noted by Ricklin and Lambris, “insufficient, excessive or poorly controlled complement 
activation can tip the balance between health and disease and lead to self-attack of host cells” 18. 
Loss of function in complement components has been shown to increase susceptibility to recurrent 
bacterial infections, while aberrant complement activation is implicated in a host of acute and 
chronic diseases that aren’t confined to necessarily confined to any specific tissue type or bodily 
region. Local and systemic activation of complement is involved in numerous autoimmune, 
inflammatory, and neurodegenerative diseases 3. Due to the diverse range of ligand activators, 
classical complement pathway genes are shown to be upregulated in many of these disease models 
with frequent association with mutations in complement regulatory proteins, triggering an 
overactive immune cell response. Further assault and damage to host tissues by the immune system 
may generate even more complement-stimulating molecular patterns exacerbating the cycle of 





Classical pathway activation was first described for its role in antibody-mediated 
clearance of microbial pathogens. Though advances in high-throughput genomic analyses, new 
biodiagnostic algorithms, and greater understanding of structural complement mechanisms have 
recently unveiled that there are many other activators of the classical pathway, condensed 
descriptors of pathway activators is still often only associate with the classical pathway with 
antibody-mediated activation. Antibody-mediated immune complex formation is responsible for 
a broad range of diseases impacted by classical pathway amplification, though its role in each 
Figure 3. Involvement of classical complement activation in various disease settings. 
Dysregulation of the classical complement pathway can produce catastrophic disease in 
individual at the local or systemic level. Autoimmune, inflammatory, and neurodegenerative 
diseases caused by classical pathway overactivation can produce both chronic and acute disease 
in any bodily tissue 18. Anti-complement drug treatment options are available for the treatment 
of complement 3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), 
atypical hemolytic uremic syndrome (aHUS), and thrombic microangiopathy (TMA). 
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disease setting is complex and varied. Circulating C1 binds antibody-antigen immune complexes 
via C1q, which is tagged by classical pathway opsonins C4b and C3b for clearance by 
professional phagocytes. By binding the targeted cell surface, the opsonigenic classical pathway 
components provide a binding site for complement receptors 1, 3, and 4 (CR1, CR3, CR4) found 
on erythrocytes, leukocytes, and splenic follicular dendritic cells (FDCs) for engulfment and 
destruction 15. The CNS inflammatory disease, neuromyelitis optica, is initiated by IgG 
autoantibodies against water channel protein aquaporin-4 in complex with activated C1. 
Classical pathway activation drives MAC formation and lysis of oligodendrocytes and neurons 
19. In similar fashion, the autoimmune disease, bullous pemphigoid, is characterized by the 
activation of the classical pathway by C1q binding to IgG autoantibodies targeting the dermal-
epidermal-junction, resulting in severe pruritus, urticarial plaques, and the development of tense 
bullae 20. 
 Beyond immune complex mediated activation, the classical pathway acts to prime the 
adaptive immune response by decorating antigens with complement fragments that induce B cell 
activation. Complement receptor 2 (CR2), found on B-cells, ligates to C3 degradation products 
(inactivated C3b (iC3b) and decaying fragments of iC3b (C3dg and C3d)) 21. Upon protein-
ligand binding, co-stimulatory signals are released that reduce the threshold for B cell receptor 
triggering. Follicular dendritic cells also present CR2 on their surfaces, and antigens presented 
by follicular dendritic cells aid in clonal selection and affinity maturation of activated B cells 
further amplifying B cell response 22. Heparin-induced thrombocytopenia is a prothrombic 
disorder resulting from complications with heparin therapy. Platelet factor 4/heparin complexes 
are recognized and bound by circulating C1q, thereby activating the classical pathway. C3 
degradation products bind CR2, forming platelet factor 4/heparin-B cell complexes, generating a 
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severe, life-threatening immune response 23. Ischemia-reperfusion organ injuries, such as 
myocardial infarction, stroke, and peripheral vascular disease, are marked by tissue injury and/or 
death amplified by surface-bound complement fragment activity 24. The classical pathway is 
thought to augment pathogenesis through C1q-IgM binding to neoantigens exposed on ischemic 
tissue. Studies have shown that inhibition of C1r and C1s reduce early tissue damage and 
recruitment/activation of dendritic cells to ischemic tissue 25.  
Another complement-linked problem can occur due to complement anaphylatoxins, C3a 
and C5a, which stimulate T cell proliferation through T cell-expressed C5a receptor (C5aR) and 
C3a receptor (C3aR) signaling for the activation, differentiation, and expansion of CD4+ Th1 
cells, increasing the strength of T cell immune response 26. There are numerous diseases driven 
by the effector role of anaphylatoxins, which is to stimulate the degranulation of endothelial 
cells, mast cells, and phagocytes producing an inflammatory response that can be either local, as 
with acute myocardial infarction 27, or systemic, such as with SIRS and sepsis 28, though the 
latter two involve the contribution of all three pathways.  
Genetic mutations in regulatory complement proteins, such as C1INH, factor H, CD46, 
CD55, and/or CD59, are associated with gain of function in complement components and are 
causal in a multitude of complement-related disorders: C3 glomerulopathy results from 
complement factor H gene mutations, while paroxysmal nocturnal hemoglobinuria results from a 
mutation in a gene controlling CD55 and CD 59 29,30. Mutations in genes that encode 
complement regulators factor H, factor I, complement factor H-related proteins, and membrane 
cofactor protein and mutations encoding for complement activators complement factor B and C3 
are causal in atypical hemolytic uremic syndrome 31.  
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Classical complement’s role in neurodegenerative disease is linked to and initiated by the 
accumulation of cellular debris, as is seen in multiple sclerosis, schizophrenia, Parkinson’s 
disease, and Alzheimer’s disease, among others 32–35. In the case of Alzheimer’s disease, the 
hallmark extracellular amyloid-β peptide deposits (Aβ) and intracellular neurofibrillary tangles 
evoke colocalized C1q deposition independent of antibody response 36,37. Owing to previous 
studies that suggest complement-mediated synaptic pruning from stages of early brain 
development are causally reactivated in adult Alzheimer’s brains, and that, tauopathy correlates 
with neurodegeneration in this disease setting, it is similarly suggested that complement 
activation mediates neuron loss in tauopathy models 36,38,39.  
Upon recognition of amyloid-β plaque and neurofibrillary tangle aggregates, C1q surface 
deposition occurs to initiate clearance of the peptidic debris. However, gross accumulation of 
cellular damage can trigger the overactivation of the classical pathway, which serves to initiate 
further insult to host neurons by recruitment and activation of inflammatory microglia and 
reactive astrocyte species (A1) to healthy tissues, especially within the hippocampus 40. Ensuing 
cellular damage induces greater production of complement components by glial cells, resulting 
in a vicious cycle of complement activation and astrocytic degradation to host synapses 36. In 
response to acute insult, astrocytes undergo transformation into a ‘reactive astrocyte’ state 
differentiated by classification as either an A1 or A2 astrocyte. A1 astrocytes are strongly 
neurotoxic and have been demonstrated to highly upregulate classical pathway cascade genes in 
conjunction with synaptic destruction, leading to the theory that complement mediates 
neurodegeneration in response to tauopathy and amyloidosis 40. Indeed, when C1qa gene is 
selectively inactivated in transgenic murine models of Alzheimer’s disease, a reduction in 
neuropathology and inflammation is seen in the hippocampus of late-stage Alzheimer’s models 
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41. Similarly, when C3 gene is knocked out, partial rescue of synapses and amelioration of brain 
atrophy protects against neurodegeneration when compared to wild-type Alzheimer’s disease 
models (Figure 4) 42. The heavy colocalization of classical pathway components with A1 
astrocytes to amyloid-β plaques and neurofibrillary tangle aggregates in the hippocampus is of 
great significance in dementia and Alzheimer’s disease. Damage to this region detrimentally 
affects “memory, navigation, exploration, imagination, creativity, decision-making, character 
judgments, establishing and maintaining social bonds, empathy, social discourse, and language 
use” 43. 
The classical pathway has also been implicated in Alzheimer’s disease through its 
interactions with apolipoprotein-E (ApoE). ApoE is an endogenous protein that is primarily 
involved in lipid transport and cholesterol metabolization. However, ApoE plays an additional 
role as a potent classical pathway checkpoint inhibitor by specifically binding and inhibiting C1q 
with high affinity at physiological concentrations and no other complement proteins of the lectin 
or alternative pathways 44. The presence of C1q-ApoE complexes observed in the human 
Alzheimer’s disease plaques is indicative of persistent classical pathway-specific activation. 
Further insight into the links between ApoE and the classical pathway have revealed that 
Alzheimer’s disease neuropathies exhibit positive correlations between lipid burden in the 
choroid plexus of the brain and degree of cognitive impairment 44. These extracellular lipids are 
recognized by C1q in the Alzheimer’s diseased brain and serve as another platform to initiate 
inappropriate activation of the classical pathway. High lipid burden also correlates with the 
ApoE4 isoform variant, which imparts a genetic predisposition to late onset Alzheimer’s disease 
through a loss of function in the transportation and clearance of lipid deposits in the brain 
14 
 
yielding an appreciable connection between the ApoE genotype, classical pathway activity, and 
risk of developing Alzheimer’s disease 44.  
Given the vast nature of complement’s role in multivariate disease progression, greater 
concerted efforts in research are being directed towards complement-targeted therapeutics. 
Increased understanding of disease mechanisms/triggers and complement’s involvement in 
driving or amplifying pathogenesis underscores the importance of tailoring anti-complement 
therapeutics for the specific disease indication. Complement involvement in Alzheimer’s disease 
is shown to be solely mediated by the classical pathway with early components imperative for 







1.3 Complement therapeutics 
The increasing awareness for the necessity of complement-based therapeutics has led to 
an upsurge in research and development of complement drugs. Currently, there are over 40 
different published drug candidates for varying complement targets within the three pathways in 
Figure 4. Complement-mediated synaptic loss in Alzheimer’s models. Aberrant 
complement deposition products that promote pro-inflammatory immune response is hallmark 
of complement dysregulation in disease. In Alzheimer’s disease, classical pathway components 
colocalize with synapses in proximity to plaques, resulting in the recruitment of neurotoxic A1 
astrocytes, and resultant synaptic destruction and loss. Similarly, neurodegeneration and A1 
astrocyte activity mediated by classical pathway is greatest in the presence of neurofibrillary 
tangles. C3 KO models demonstrate synaptic rescue and subsequent neuroprotection 36. 
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various stages of clinical development 46. Intervention in the pathways, however, has shown to 
be full of complexities, and despite the significant interest, only two complement drugs have 
made it to market. In 2007, the FDA approved the first anti-complement drug, eculizumab 
(Solaris, Alexion). Eculizumab was synthesized and developed as fully humanized anti-C5 
monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria and atypical 
hemolytic uremic syndrome 47. The acquired deficiency of glycosylphosphatidylinositol in 
erythrocytic membranes leads to an absence of complement regulators CD55 and CD59 that 
prevent hemolysis by complement in individuals with paroxysmal nocturnal hemoglobinuria. By 
preventing the cleavage of C5, eculizumab inhibits the formation of the lytic terminal 
complement component, MAC, and eliminates generation of the C5a anaphylatoxin, thereby 
preventing lysis of erythrocytes 48.  Despite the success of eculizumab, its introduction to the 
market has brought to light new challenges in anticomplement drug development. One area of 
concern is the iatrogenic hemolysis of paroxysmal nocturnal hemoglobinuria platelets in 
extravascular compartments by macrophages due to C4b and C3b opsonization 30. Additionally, 
during acute infections where complement activation is high, “breakthrough” hemolysis has 
occurred regardless of increased drug dosing . Confounding factors in disease mechanisms 
increase the complexity of drug development, but also highlight the need for additional disease-
tailored drugs. At present, alternative anti-C5 therapeutics are a major target of pharmaceutical 
companies. 
Inhibition of the complement pathway at the C3 level also dominates anticomplement 
drug research and development for its broad implication in the amplification of all three 
pathways, its impact on cell-mediated and humoral immunity, and the generation of 
anaphylatoxin, C3a, and opsonin, C3b. Currently, there are several anti-C3 drugs being evaluated 
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in phase II and phase III trials for treatment of issues such as ischemic disorders, tumor 
immunosuppression, and autoimmune disorders 49. Yet, targeting the complement convertases 
located centrally and terminally in the pathways neglects diseases mediated by upstream classical 
pathway and lectin pathway-specific components, and due to the complexity of pathological 
mechanisms underlying complement-mediated disease, the need still stands for disease-specific 
complement regulators 50.  
One drug that fills the role of targeting upstream components is C1-esterase inhibitor 
(C1-INH) (Cinryze). The complement drug field has also seen success with recombinant and 
plasma-purified C1-INH with the objective of supplementing endogenous C1-INH deficiency for 
the treatment of non-complement-mediated disease in patients with type I and II hereditary 
angioedema 51. C1-INH is a plasma serine protease inhibitor with broad specificity beyond C1 
inhibition. In addition to classical pathway inhibition, C1-INH also targets the lectin pathway, 
and coagulation, kinin and fibrinolytic cascades. Due to its broad specificity, C1-INH (Berinert) 
is also being studied for its application in other complications and disease settings where the 
classical and/or lectin pathway are implicated, such as delayed graft function in kidney 
transplantation to attenuated inflammatory markers and kidney ischemia-reperfusion injury 49. 
Even with its successes, the inability to effectively act upon a restricted target presents 
specificity issues common across the board for the development of all serine protease inhibitors. 
Serine proteases, C1r and C1s, serve as initiators of the classical complement pathway 
upon activation. Developing inhibitors of these proteases prevents the release of classical 
pathway-mediated pro-inflammatory cytokines and halts the proteolytic cascade before it can 
become inappropriately activated. Autoantibodies, as well as amyloid-β/neurofibrillary tangle 
aggregates, have been well-documented in numerous disease settings to drive classical pathway 
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overactivation, triggering inflammatory disease progression. Due to pathway specificity, 
especially in that of Alzheimer’s disease, the initiating proteases serve as promising targets 
anticomplement targets for ameliorating pathogenesis. Currently, anti-C1q antibody, ANX005 
(Annexon Biosciences), and monoclonal anti-C1s antibody, TNT009/BIV009 (True North 
Therapeutics), are in phase I and phase III clinical trials for treatment of Guillain Barré syndrome 
and cold agglutinin disease, respectively 49. It stands to reason that their upstream classical 
pathway inhibition may prove to be both applicable and therapeutic in other classical pathway-
mediated disease settings. However, antibody-based drugs face challenges with dosage and 
tissue penetrance when mediating complement in disease. 
Though inhibiting the serine proteases of C1 halts only the activation of the classical 
pathway, leaving the other pathways open for immune protection, classical pathway complement 
serves an important role in elimination of bacterial pathogens. One potential problem arising 
from classical pathway inhibition is greater susceptibility to bacterial pathogenesis. Eculizumab 
trials showed that susceptibility to infection can be overcome by dosing the patient proactively 
and/or concurrently with constant antibiotic treatment and vaccinations against likely bacterial 
invaders 50. Additionally, early classical pathway genes are also seen upregulated in early stages 
of Alzheimer’s disease, and studies with C1q-knockout models, show marked increases in 
amyloidosis and tauopathy in contrast with wild-type models, implicating clearance of cellular 
debris as another important functional role of classical pathway 52. However, research has shown 
that amyloid-β plaques and neurofibrillary tangles can persist in the brain without cognitive or 
motor impairment, so long as inflammation and neuronal loss is attenuated by eliminating 
classical pathway opsonization 36. Complement’s roles in synaptic pruning are no longer 
essential to adult brain development and inhibition of classical pathway conversely shows 
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neuroprotective activity against traumatic injury and age-related neurodegeneration 40. Another 
risk that has been under discussion is that classical pathway inhibition may increase vulnerability 
to unforeseen other pathologies, such as systemic lupus erythematosus stemming from the 
genetic deficiency of C1q 53. However, there has yet to be evidence that C1q deficiency that is 
acquired later in life, versus as a genetic defect, has any link to systemic lupus erythematosus or 
similar complications. The greatest issue that arises from targeting serine proteases is off-target 
risks from increased penetrance and cytotoxicity due to lack of inhibitor specificity. Currently, 
there are a number of drugs trying to overcome this challenge by creating small-molecule 
inhibitors capable of being optimized to increase specificity 54.  
1.4 Small-molecule inhibitors 
The traditional route for developing protease inhibitors is the identification of small-
molecules that block the action of the protease by binding the active site 54. The development of 
small-molecule inhibitors as a drug provides promising results for complement regulation. The 
low-molecular weight yields the benefit of diffusion across cellular membranes, which is 
especially important for transport across intestinal epithelial cells for oral drug administration, 
and for the potential to cross the blood brain barrier, for neurodegenerative disease targets 
marked by blood brain barrier injury and permeability. Larger biologics such as recombinant 
proteins and monoclonal antibodies are unable to freely travel across membranes and often 
require local injection to the disease site 50. Additionally, Fab fragments of monoclonal 
antibodies have inherently short half-lives and are not a “tunable pharmacologic intervention” as 
are small-molecules, which also allow for better titration 55. Small-molecules have the advantage 
in that they can be developed for oral bioavailability in which they are able to travel 
systemically. Complement has inherently high turn-over, especially of C3 due to the positive 
20 
 
feedback amplification loop, which allows for clearance of the small-molecule inhibitor so that 
complement function can be restored after the disease is cleared and the drug regime halted 50.  
Complement turn-over is very rapid and during acute infection or acute disorders, 
complement can be produced rapidly and in great quantities in the blood. High concentrations of 
complement components can place a strain on dosing requirements. Typically, monoclonal 
antibodies must be delivered to the patient in single subcutaneous injections limited to one to two 
mL volume of antibody at between 100 and 150 mg/ml (approximately two - three mg/ml in 
humans), whereas some complement fragments, such as C5, can circulate in concentrations of 90 
to 172 mg/L of blood 47. This differential creates shortcomings in treatment of certain diseases 
with antibody-based drugs. Small molecules, on the other hand, can be orally dosed and 
concentrations titered to meet disease demands. In chronic disease models, small-molecule 
inhibitors may provide the best therapeutic option as an orally available drug that can be taken 
regularly 51.  
Molecular weight of the small-molecule is an important consideration and the small size 
also allows for optimization of the compound to increase specificity and binding affinity to the 
target. Fragments, which are characterized as having a molecular weight of less than 300 Da and 
high solubility, have been especially efficacious in this endeavor 56. Compounds that form 
aggregates in solution limit the accuracy of surface plasmon resonance (SPR) binding kinetics by 
causing false positives at high concentrations 57. Utilizing x-ray crystallography to attain high-
resolution crystal structures of the target protein, the molecular complexities of protein-protein 
interaction mechanisms, as well as critical surface target sites, can be attained to drive structure-
based fragment design 58. However, the formation of protein crystals capable of diffraction can 
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be challenging and required the production of pure, functional, homogeneous protein suitable for 
screening and structure determination 56.  
Specificity has proven to be a challenge in inhibiting serine protease activity with off-
target effects and toxicity being the main obstacles to overcome. Nafamostat mesilate (futhan) is 
a small-molecule protease inhibitor used for treatment of disseminated intravascular coagulation 
and acute pancreatitis that affects multiple plasma protease systems. Yet, due to its broad 
specificity, cytotoxicity results in vivo, making it a poor drug target 59. Fragments also lack great 
specificity as well as low binding affinity that larger compounds may possess. However, because 
of these qualities, they are more likely to bind a target than a larger molecule. Moreover, 
fragments have the advantage of being optimized to increase those characteristics using one or 
more of the three existing strategies for fragment optimization – fragment linking, growing, and 
merging 60. And due to their small size, researchers have more starting fragments to work with 
and more opportunities to make better quality decisions for generating lead compounds. 
Accordingly, there are many compounds currently under evaluation in clinical trials that were 
developed from fragments-based drug discovery 61.  
1.5 Structure-based drug design  
The molecular mechanisms by which complement is activated and drives pathology is 
critical for selecting and designing effective inhibitors of the initiating proteases. The molecular 
structure of enzymes is essential for deriving active sites and binding sites, and conformational 
changes during activation is key to design an inhibitor capable of interacting with sites that 
undergo those changes. Small nuances in the structure of the active site can lead to enormous 
implications as to what can ligate near or within the site 62. Structure-based drug design hinges 
entirely on the solved, high-resolution structure of the protease, and x-ray crystallography is the 
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best tool to achieve that end. High-resolution x-ray crystallography defines the electron density 
of a given amino acid allowing for researchers to visualize bond angles/constraints and most 
likely conformation of rotamers, which are side-chains that adopt preferred conformations based 
on local energy minima 63. Many crystal structures of various enzymes have been published 
along with their consequent mutations. Both C1r and C1s crystal structures have been produced 
and characterized for enhanced understanding of structure and activation mechanisms.  
To optimize the development of our small-molecule inhibitors, we opted for structure-
based drug design utilizing published crystal structures of C1r and C1s. Because we are looking 
to specifically target the proteolytically active serine protease domains of both C1r and C1s, we 
created biologically functional CCP2-SP domain truncations. Ideal crystal conditions and 
compound concentrations can allow for empirical binding data through effective co-
crystallization of inhibitors in complex with C1r and C1s. Co-crystallization provides true 
binding poses and binding locations of inhibitors and opens the possibility of identifying binding 
sites not previously screened for 64. Understanding these binding conformations in fragment-
based drug design can also provide the basis for merging two compounds across relevant sites on 
the protease to increase specificity, binding affinity, and protease inhibition 65. 
In one area of study, C1r inhibitors were assessed using a structure-dependent fragment-
based drug discovery approach to screen compound libraries for fragments predicted to bind 
serine proteases based on known structures. This method allowed for identification of compound 
hits custom-selected for favorable physicochemical properties for serine protease inhibition. By 
employing this approach, hits were more frequently generated than in high-throughput screening, 
though they possessed relatively weak binding affinities, necessitating further optimization 55.  
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In a separate, orthogonal approach, we used computational cheminformatics to generate a 
list of priority compound leads from in silico libraries that index compound information to 
deliver predictive information about compound docking. Compounds computationally evaluated 
to bind within specified regions of C1s were derived from published program database (PDB) 
crystal structures with defined active sites. This method allowed for prioritization of hits via 
quantification of averaged predicted binding energies with C1s and favorable binding poses. 
Both methods have been used successfully in the advancement of small-molecule drug 
development 55,61,66. 
The aim of this study was to identify small-molecule inhibitor leads of the initiating 
proteases, C1r and C1s, of the classical complement pathway and optimize those leads to pave 
the way for future drug development. We screened thousands of compounds through complex 
fragment-based libraries and employed cheminformatics to triage potential small-molecule leads. 
Using surface plasmon resonance, ELISA-based inhibition assays, enzymatic cleavage assays, 
hemolysis assays, and x-ray crystallography, we narrowed our leads to those with 
physicochemical properties that lent favorable drug-like qualities. Through our study, we have 
discovered four novel small-molecule compounds that display favorable binding affinities and 





Figure 5. Pathway inhibition at the level of the initiating proteases of the classical 
pathway. (A) Use of a small-molecule inhibitor on C1r halts the autoactivation of C1r upon 
antigen recognition and binding. Downstream complement products would be significantly 
reduced in diseases exacerbated by classical pathway involvement and potentially arrested 
entirely in diseases mediated by the classical pathway. (B) The arrangement of C1r and C1s 
dimers in the C1 complex allows for ease of accessibility by inhibitors. The exposed serine 
protease domains on the C-terminus of C1r2C1s2 provide a favorable binding target. Figure 5 





CHAPTER 2: MATERIALS AND METHODS 
2.1 Recombinant expression, purification, and refolding of C1r-domain truncations 
Recombinant C1r-domain truncations of the CCP2-SP domains were produced by 
subcloning DNA oligonucleotides flanked with a 5’ BamHI site, a 3’ NotI site, and a stop codon 
into the pT7HMT vector. The plasmids were transformed into E. coli BL21 and plated for 
incubation overnight at 37ºC. The bacterial colonies were grown in lysogeny broth (LB) (10 g/L 
trypton, 5 g/L yeast extract, 5 g/L sodium chloride) and transferred to Terrific Broth (TB) (11.8 
g/L tryptone, 23.6 g/L yeast extract, 9.4 g/L dipotassium hydrogen phosphate, 2.2 g/L potassium 
dihydrogen phosphate) supplemented with kanamycin. 
The cultures were induced with isopropyl β-D-thiogalactoside once they had reached an 
optical density of 0.6-0.8. The cultures were then incubated and stirred overnight at 37ºC and 
later spun at 6,000 x g for 10 minutes. The supernatants were poured off and 100 mL denaturing 
lysis buffer (6 M guanidine HCL, 100 mM Tris pH 8.0, 10 mM imidazole pH 8.0) was added per 
protein prep to the remaining bacterial pellets. The pellets were resuspended, and the lysates 
centrifuged at 13,000 x g for 30 minutes.  
Nickel affinity columns with 10 mL nickel resin slurry were prepared by first washing 
with 50 mL denaturing binding buffer (20 mM sodium phosphate pH 6.0, 500 mM NaCl, 8 M 
urea, 10 mM imidazole pH 8.0). Lysates supernatants were dispensed onto the nickel columns 
and flow rate was adjusted to 1-2 drops per second. After the total lysate had passed through the 
column, the column was then washed with 25 mL denaturing binding buffer. Two mL denaturing 
elution buffer (20 mM sodium phosphate pH 6.0, 500 mM NaCl, 8 M urea, 200 mM imidazole 
pH 8.0) was passed through the column, and 5 mL denaturing elution buffer subsequently passed 
through and collected into a 50 mL conical tube at a drop rate of 1-2 drops per second.  
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50 mL of 2SP refold buffer (50 mM Tris pH 8.3, 3 mM reduced glutathione, 1 mM 
oxidized glutathione, 5 mM ethylenediaminetetraacetic acid (EDTA), 500 mM arginine) was 
freshly prepared and added to each 5 mL eluate sample and allowed to sit at room temperature 
overnight. The 50 mL 2SP samples were then transferred into 3.5K dialysis tubing and dialyzed 
against 4 liters of 2SP refold buffer #2 (50 mM Tris-HCl pH 7.4, 145 mM NaCl) for 4 hours. The 
samples were then placed in freshly remade 2SP refold buffer #2 to dialyze overnight. 
The 2SP samples were concentrated down to 12 mL final volume using 3.5K MWCO 
centrifuge spin filters and purified by gel filtration column on FPLC. Activated (+DTT) TEV 
was exchanged in native binding buffer (10mM imidazole, 500 mM NaCl) and 50 µL was 
incubated overnight at 25oC with pooled peak gel filtration fractions to remove the polyhistidine 
tag (His-tag). 
The 2SP samples were then concentrated to 12 mL once more and run through the FPLC 
nickel column to collect the “untagged” protein contained in the flow-through. The pooled peak 
was then concentrated to a final volume yielding less than 1.5 mL of purified, refolded 2SP. To 
confirm proper refolding of SDS-PAGE gel electrophoresis was run with C1r-CCP2-SP under 
reducing and nonreducing conditions (Figure 6). Under nonreducing conditions, a band present 
at 38 kDa, is seen, matching the molecular weight of the C1r domain truncation, Lane 2. When 
properly purified and refolded, under reducing conditions, Lane 4, the disulfide bridge between α 
and β chains of C1r-CCP2-SP is broken resulting in the expected protein product bands at 29 




2.2 Compound library 
The initial screen of ChemDiv compound library yielded 2,000 small-molecule or 
fragments hits predicted to bind C1r. Those compounds were purchased and received as powder 
and resuspended in dimethyl sulfoxide (DMSO) to a final concentration of 10 mM and stored at -
20oC. The structural analogues of lead compounds, cmp-1611, cmp-1663, comp-1696, and cmp-
Figure 6. SDS-PAGE gel electrophoresis of refolded C1r-CCP2-SP under reducing and 
nonreducing conditions. The domain truncation, C1r-CCP2-SP, has a molecular weight of 38 
kDa, as seen in nonreducing conditions, Lane 2. When purified and refolded, under reducing 
conditions, Lane 4, the disulfide bridge between α and β chains of C1r-CCP2-SP is broken 
resulting in the expected protein products at 29 kDa and 13.5 kDa. SDS-PAGE gel 
electrophoresis confirms proper protein refolding during synthesis under reducing conditions. 
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1827 were identified in ChemDiv’s compound library using structural similarity search 
parameters. Those analogues were also purchased, received, resuspended to 10 mM in DMSO, 
and stored at -20oC. 
2.3 Surface plasmon resonance 
SPR experiments were conducted using a Biacore T200 (GE Healthcare) at 25oC and 
HC1500M sensor chips (Xantec). All experiments were performed using a running buffer (HBS-
T) of 20 mM HEPES, 140 mM NaCl, 0.005% Tween-20, 5% DMSO. At the start, finish, and 
every 50 cycles through the duration of the experiment, DMSO calibration curves ranging from 4 
to 5.5% DMSO were collected. Over the course of this study, 13 sensorchips and 21 ligand 
immobilized surfaces were created in total. In all cases, C1r or C1s proteins were immobilized 
onto chip surfaces using amine-coupling chemistry with 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide) (EDC), N-hydroxysuccinimide (NHS), and ethanolamine. Briefly, 100 mM of 
EDC and NHS were mixed and injected to activate the chip surface followed by the C1r or C1s 
protein ligand captured at a defined resonance unit (RU) level, followed by reaction quenching 
with 100 mM ethanolamine pH 8.5. Flow cell 1 was always used as a reference cell (no ligand) 
unless otherwise noted. All sensorgrams were reference and blank subtracted and analyzed using 
T200 Evaluation Software (GE Healthcare). 
2.4 SPR screening of C1r-binding compounds 
Five µL of each of the 2,000 10 mM compound fragment hits were diluted in 95 µL of 
HBS-T in 96-well plates to yield 500 µM solutions with a final DMSO concentration of 5% to 
match the running buffer. The compounds were then visually inspected for solubility in running 
buffer and insoluble compounds were discarded from the “clean screen.” Using an uncoupled 
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HC1500 SPR chip, compounds were injected over a single flow cell to assess nonspecific 
interactions with the chip surface. Compounds that exhibited >5.0 RU of residual binding at 10 s 
post injection were removed from the screen. The remaining 1,600 compounds were injected 
over the chip with 500 µM full-length C1r immobilized at the surface to test for binding affinity 
to C1r. Baseline noise was accounted for using T200 evaluation software. A theoretical maximal 
binding signal (Rmax) was calculated using the equation Rmax = (C1r immobilization level (RU) x 
(mol wtcompound / mol wtC1r) * n), where mol wtC1r = 92,000 Da, and n is the binding 
stoichiometry, assumed here to be 1. Compounds were triaged as hits if all the following criteria 
were met: injections fell within the DMSO calibration curve, did not exhibit > 5.0 RU of residual 
binding to the reference surface, did not exhibit abnormal sensorgram shape, and did not exhibit 
superstoichiometric binding. 
 2.5 Evaluation of dose-dependent binding by SPR 
To test for dose-dependent binding, hit compounds were injected over three replicate 
flow cells containing both high and low immobilization densities of C1r. Nefamostat/FUT-
175/futhan (Sigma Aldrich) is a promiscuous serine protease inhibitor previously reported to 
bind to C1r. We obtained dissociation constants for futhan/C1r and futhan/C1r-CCP2-SP in our 
SPR-based assay to establish an appropriate control injection of futhan at a saturating 
concentration. Futhan was then subsequently used in each experiment at 10 µM to monitor inter-
plate instrument and biosensor performance. Triaged compounds were tested for dose-dependent 
binding to full-length C1r and/or C1r-CCP2-SP using a compound concentration range of 7.8 to 
500 µM. T200 evaluation software was used to calculate steady-state affinities for each 
compound by fitting sensorgrams from each variable concentration injection dataset using a 1:1 
Langmuir model of interaction constrained by a maximal experimental binding response (Rmax) 
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derived from 10 µM futhan injections and corrected for the molecular weight of each individual 
compound. 
2.6 Molecular docking 
Molecular docking of compounds into the C1r domain truncation model (C1r-CCP2-SP; 
PDB: 1GPZ) was performed using AutoDock Vina 1.1.2. based on the given coordinates for the 
center of the protein structure [46, 14, 30] and size [74, 64, 54 in Å] of the target box in WinCoot 
0.8.6.1. using the superpose function 67,68. Protein structures were prepared using PyMOL 
Molecular Graphics System, Version 2.0 Schrödinger, LLC.  
2.7 Complement inhibition assay 
High-binding 96-well ELISA plates were immobilized with 3 µg/mL IgM dissolved in 
coating buffer (100 mM Na2CO3/NaHCO3, pH 9.6) dispensed in 100 µL volumes per well and 
incubated overnight at 25oC. The plates were then washed three times in washing buffer (50 mM 
Tris pH 8.0, 200 mM NaCl, 0.05% (v/v) Tween 20) and blocked using 100 µL of 1% bovine 
serum albumin in PBS-T for one hour at 37oC. The plates were washed three times with washing 
buffer, and in a non-binding 96-well plate, two-fold dilutions of our 10 mM compounds were 
prepared using 5 µΜ compound in 95 µL classical complement ELISA buffer (20 mM HEPES 
(pH 7.3), 0.1% (w/v) gelatin, 140 mM NaCl, 2 mM CaCl2, 0.5 mM MgCl2) and 1.05% normal 
human serum. Row G was utilized as a positive control for full classical complement activity, 
and Row H was utilized as a negative control for no classical complement activity. The samples 
were transferred to the blocked ELISA plates and incubated for 1 hour at 37oC. The plates were 
then washed three times in wash buffer and 100 µL anti-C4 antibody diluted 1:300 in PBS-T was 
dispensed into each well. The plates were incubated for 1 hour at 37oC, washed three times in 
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wash buffer, and filled with 100 µL of HRP-conjugated goat-α-mouse secondary antibody 
diluted 1:3000. The plates were rocked for 1 hour at 25oC, washed three times, and then filled 
with 100 µL 1-step Ultra TMB. The plates were rocked for 15 minutes in the dark at 25oC. The 
reaction was halted with 50 µL of 0.16 M sulfuric acid and the plate read at 450 nm using an 
EnSight multimode plate reader. Positive controls (1% serum, no inhibitor) were defined as 
100% C4b signal whereas negative controls (0% serum) were defined as 0% C4b signal for each 
column. 
Compounds that inhibited C4b deposition relative to the control were then evaluated using 
the same assay setup across a two-fold variable concentration curve of each compound (7.8 to 500 
µM). These data were used to obtain half-maximal inhibitory concentrations (IC50’s) by fitting 
dose-response curves using inhibitor vs. response models in GraphPad Prism 7. All experiments 
were performed in triplicate. 
2.8 C1r and C1s enzyme assay 
Individual stock solutions of 1 mM of Z-Gly-Arg-sBzl (MP Biomedicals) and 5,5′-
Dithiobis (2-nitrobenzoic acid) (DTNB) (Sigma-Aldrich) were made by dissolving powder in 
DMSO to give 10 mM stocks of each compound which were then diluted to 1 mM in assay 
buffer (50 mM tris-HCl pH 7.5). Full length C1r or C1r-CCP2-SP were dissolved in assay buffer 
to give stocks of 20 nM and 15 nM respectively. The 100 mM compound stocks (in DMSO) 
were pipetted in triplicate in 2.5 µL volume into a 96-well plate. Full-length 20 nM C1r or 15 
nM C1r-CCP2-SP solutions were added to the wells in 25 µL quantities, along with 12.5 µL 
assay buffer. In a separate reservoir, equal volumes of 1 mM DTNB and 1 mM Z-Gly-Arg-sBZL 
were mixed, and 10 µL was added to each well to initiate the reaction. Plates were read at 450 
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nm using an EnSight multimode plate reader (Perkin-Elmer) every 30 seconds for 30 minutes 
after the reaction was initiated. Positive controls (no inhibitor, enzyme only) and negative 
controls (no enzyme) were defined as 100% and 0% signal for each column, respectively. For 
C1s, the assay buffer was HBS-T (20 mM HEPES, 140 mM NaCl, 0.005% Tween-20) plus 5 
mM CaCl2. A final C1s concentration of 5 nM was used for the reaction and Z-L-Lys-sBzl (MP 
Biomedicals) was used as a substrate at a final concentration of 100 µM. 
2.9 Compound similarity analysis 
Cheminformatics was employed independently of the compound library screen using 
Chemalytic’s in silico approach to identify highly-specific compounds predicted to dock near or 
within the C1r-2SP catalytic cleft through the published C1r-domain truncation crystal structure. 
Compounds are identified from the ZINC database and docked in favorable conformations and 
their theoretical binding affinities calculated and prioritized. 
2.10 X-ray crystallography 
Using a 3K MWCO spin filter, C1r2SP was spun at 13,000 x g for 5 minutes to 
concentrate the sample volume down to 100 – 200 µL and a final concentration of at least 3 
mg/mL, after correcting for the extinction coefficient. The protein solution was pipetted in a 
crystal sample tube and with the lead compound and dispensed onto the tray at a 1:1 mix of 
protein to mother liquor in the top well and a mix of 2:1 in the bottom well. Several 
crystallization conditions were identified with two conditions producing the most promising 
crystals to work with. The first condition contained 0.2 M sodium acetate trihydrate, 0.1 M Tris 
hydrochloride pH 8.5, 30% w/v polyethylene glycol 4,000 and the second contained 0.2 M 
magnesium chloride hexahydrate, 0.1 M Tris hydrochloride pH 8.5, 30% w/v polyethylene 
glycol 4,000. Small plate clusters reproducibly appeared within 24 hours and were harvested and 
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cryoprotected with supplementation of 5% glycerol to the precipitant solution. Crystals in this 
condition grew in the space group P 2 21 21 with one copy of the C1r-CCP2-SP molecule in the 
asymmetric unit diffracting at 1.8 Å. 
2.11 C1s in silico docking experiment 
Using published crystal structures of C1s, Chemalytic’s software utilized AutoDock Vina 
to computationally screen 4.27 million compounds from the ZINC database for predictive 
binding to the C1s dimer interface, C1s/C1q interface, C1s/C1r interface, and the C1s scissile 
loop. The compounds were overlaid within each of the four sites and their calculated C1s-
binding energies were ranked. Compounds that scored 4.5 standard deviations above the average 
docking score underwent further physicochemical analysis to calculate the xLogP values of each 
compound and ranked accordingly. Compounds with favorable theoretical C1s-binding affinity, 
physicochemical properties, and diverse chemical structures were triaged. 
2.12 SPR screening of C1s-binding compounds 
Lead compounds predicted to bind with high affinity near or within the C1s catalytic cleft 
were commercially synthesized. The compounds were then resuspended in 100% DMSO to yield 
a final concentration of 10 mM. The resuspended compounds were further diluted in HBS-T in 
96-well plates to yield 500 µM solutions with a final DMSO concentration of 5%. The 
compounds were then injected over the sensor chip with a concentration range of 7.8 to 500 µM 
and assessed as to whether they bound 500 µM immobilized full-length C1s and/or C1s-CCP2-
SP. T200 evaluation software was used to calculate steady-state affinities for each compound by 
fitting sensorgrams from each variable concentration injection dataset using a 1:1 Langmuir 
model of interaction constrained by a maximal experimental binding response (Rmax) derived 
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from 10 µM futhan injections and corrected for the molecular weight of each individual 
compound. 
2.13 Complement inhibition assay 
C1s inhibition was measured using the identical ELISA protocol used for testing C1r 
inhibition.
 
CHAPTER 3: FRAGMENT-BASED DRUG DISCOVERY APPROACH 
3.1 Small-molecule library design 
The small-molecule library design originated from a compound library of a custom-
selected, commercially synthesized, 2,000 small-molecule library (ChemDiv Inc.), and was 
chosen to encompass five subcategories based on chemical scaffolds, functional groups, 
substituent moieties, stereochemistry, conformers, and chains (Figure 7). The categories were 
defined as: i) 250 “two-dimensional fragments” (2D-FL), ii) 250 “three-dimensional fragments” 
(3D-FL), iii) 250 “serine-protease inhibitor” compounds (SPI), iv) 250 “natural product 
scaffolds” (NPB), and v) 1,000 “protein-protein inhibitor” compounds (PPI). 
Compounds in the 2D-FL library were small-molecule fragments that ranged in 
molecular weight between 99-330 Da, whereas those found in the 3D-FL category were 
fragment-sized compounds ranging in size from 109-372 Da with increased three-dimensional 
character as judged by increased sp3 hybridized carbons, which lends three-dimensionality and 
complexity to the library (44). Small molecules from the SPI category were selected based on 
scaffold similarity to known serine protease inhibitors and ranged in size from 164-575 Da. 
Compounds from the NPB category ranged in molecular weight from 221-568 Da and were 
chosen for their scaffold structural similarity to natural product-derived compounds. The PPI 
library was made up of compounds with physicochemical properties similar to those of known 
protein-protein inhibitors. The compound categories were selected for their diverse and potential 





Figure 7. Study workflow of fragment-based drug discovery approach. Identification of 
small-molecule leads targeting C1r-CCP2-SP domain originated from a screen of commercially 
available fragments. Using stepwise biochemical and functional validation assays, the list of 
compound leads was narrowed from 2,000 fragments to four that displayed dose-dependent 
binding and inhibition. By identifying key structural components of each compound, an 




3.2 Initial library screening of C1r-binding by SPR  
Compounds that were selected for in the initial compound library screen were further 
triaged in an SPR “clean screen” to eliminate those with non-specific binding characteristics 
and/or poor solubility in aqueous SPR buffers (Figure 4). To first determine solubility, 
compounds were diluted to a final concentration of 500 µM in SPR running buffer (20 mM 
HEPES (7.3), 140 mM NaCl, 0.005% Tween-20, 5% DMSO). Compounds that were visibly 
insoluble at 500 µM were eliminated from future testing. Compounds that were soluble 
underwent additional screening for non-specific binding behavior by injecting the 500 µM 
compound over a blank flow cell on the SPR sensorchip for 30 seconds. Those that displayed a 
residual binding signal of > 5.0 RU at 10 seconds post injection were eliminated from future 
testing due to non-specific binding. 
         Of the 2,000 compounds that were screened, 1,619 passed the clean screen for further 
testing (Figure 8). Full-length C1r was covalently immobilized to the SPR sensorchip surface for 
the C1r binding screen by SPR and the remaining compounds were injected over the surface at 
500 µM. Binding curves of compounds that were outside of the DMSO solvent correction curve 
and those that exhibited superstoichiometric binding were eliminated from future testing. 
Compounds selection was further narrowed by theoretical maximal binding response. Those that 
showed maximal binding response greater than 60% of the theoretical maximum were 
prioritized. From the 2,000 compounds that were originally screened, 91 compounds (4.5%) 







Figure 8. SPR binding response analysis of all compounds injected over full-length C1r. 
Compounds identified from the fragment screen were evaluated for aqueous solubility and non-
specific binding via injection over a blank SPR sensorchip. Those that displayed poor solubility 
and/or non-specific binding were eliminated from the study. Remaining compounds were 
injected over a sensorchip at a concentration of 500 µM with immobilized full-length C1r. 
Using the calculated theoretical maximal binding response (Rmax), compounds that presented 
superstoichiometric binding (i.e. >2x Rmax) were eliminated, while those that achieved ≥ 60% 
Rmax and were retained (green).  
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3.3 C1r-binding and classical pathway inhibition properties of prioritized compounds 
         The prioritized compounds were further assessed for their abilities to both bind and 
inhibit C1r autoactivation (Figure 9). The binding affinities of 59 of the 91 compounds were then 
examined for dose-dependent binding characteristics in subsequent SPR analysis by injecting 
two-fold variable concentration series of each compound over immobilized C1r, and they ranged 
in concentration from 17 to 7,480 µM. The steady-state affinities were calculated from three 
independent injection series. 
An ELISA-based in vitro assay was used to determine classical pathway inhibition at a 
single dose by measuring downstream complement product, C4b, well deposition. Compounds 
were utilized in 500 μM final concentrations and optical densities (ODs) were obtained, 
quantifying the extent of classical pathway inhibition. Seventeen compounds displayed 
statistically significant complement inhibition and when serially diluted from 500 μM to 7.82 
μM final concentration, 15 of those compounds were also shown to display dose-dependent 





3.4 Identification of structurally distinct C1r-binding and inhibitory compounds 
Using the ELISA-based in vitro assay, the remaining 15 compounds were prioritized 
based on dose-dependent inhibition of the classical complement pathway. Of the 15 compounds, 
four yielded reproducible lead dose-dependent C1r-binding and inhibition (Figure 10A-D). 
These lead compounds, cmp-1611, cmp-1663, cmp-1696, and cmp-1827, were all derived from 
Figure 9. ELISA-based assay for classical pathway inhibition by compounds. Compounds 
that bound in the SPR evaluation screen were assessed in triplicate at a concentration of 500 
µΜ for classical pathway inhibition by measuring C4b deposition in ELISA-based assay. In 
total, 17 compounds were identified as classical pathway inhibitors, relative to the vehicle 
control (DMSO), as seen in green. C4b deposition reduction was statistically significant in 
inhibitory compounds using the Student’s t-test (p < 0.05). 
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the protein-protein inhibitor library, yet they remain structurally distinct from one another as 
small-molecule fragments. Compounds cmp-1611, cmp-1696, and cmp-1827 each exhibit 
favorable “rule-of-three” fragment physicochemical properties (i.e., ≤ 300 Da, ≤ 3 hydrogen 
bond donors, and ≤ 3 cLogP) (45). The remaining lead compound, cmp-1663, is larger than a 
typical fragment at 376 Da, but exhibits drug-like “rule-of-five” properties (i.e., ≤ 500 Da ≤ 5 
hydrogen bond donors, ≤ 10 hydrogen bond acceptors ≤ 5 cLogP) (46). The compounds 
displayed C1r-binding affinities (KD) ranging from 115 to 202 μM and C1r-inhibition values, 
represented by IC50 values, of 550 to 1,060 μM. Due to their favorable properties, these 






















Figure 10. ELISA-based assay for dose-dependent inhibition of CP. (A-D) The 17 
compounds were evaluated for dose-dependent inhibition of the classical pathway by utilizing 
two-fold serial dilutions of inhibitor with concentrations ranging from 10 mM to 312.5 µΜ.  
C4b deposition was used as a measure of classical pathway activity. In total, four compounds, 
cmp-1611, cmp-1663, cmp-1696, and cmp-1827 dose-dependently inhibited the classical 
pathway. Using non-linear regression analysis, inhibition curves were generated and IC50’s 
were calculated using a 95% confidence interval. Cmp-303 is plotted as a basis of comparison, 
as cmp-303 was identified as a C1r dose-dependent binding compound that displayed no 
classical pathway inhibition (KD-C1r/cmp-303 = 150 µΜ). 
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3.5 Mapping the binding site of each lead fragment on C1r 
Following confirmation of C1r binding and inhibition, we sought to identify the binding 
site of each lead compound on C1r. In order to determine the binding site, known C1r-domain 
truncations, based on solved atomic resolution crystal structures, were utilized in three 
independent in silico docking experiments as the full-length crystal structure of C1r has not yet 
been solved (Figure 11A). To isolate both binding site and C1r domain, the monomeric structure 
of the N-terminal region of C1r (CUB1-EGF-CUB2; PDB: 6F39) 11 or the C-terminal region of 
C1r (CCP1-CCP2-SP; PDB: 1GPZ) 69 and CCP2-SP (PDB: 1MD8) 70 was applied to 
AutoDockTools1.5.6 and each lead compound docked (Figure 11B). 
The predicted binding site within the N-terminal region remained within the same pocket 
on the CUB1 domain, whereas the binding site on the C-terminal region was within the 
proteolytically active serine protease domain, near or within the catalytic cleft or substrate 
specificity pocket S1 site. The binding affinities within each domain were predicted to be within 











To isolate the competitive and preferred binding site of each compound, we produced the 
recombinantly expressed C1r-domain truncations C1r-CUB1 and C1r-CCP2-SP (we were unable 
to solely produce the C1r-SP domain). Those C1r-domain truncations were then immobilized 
separately on SPR sensorchips and the lead compounds individually injected over each surface. 
The SPR binding experiment yielded differing binding affinities between C1r-CUB1 and 
C1r-CCP2-SP than that of what was predicted in the in silico docking experiments, with the lead 
Figure 11. Crystal structure of C1r-CCP2-SP provides in silico predictive molecular 
docking data for lead compounds. (A) Using the published crystal structure of C1r-CCP2-
SP domain truncation mutant (PDB: 1MD8) and known sequences of serine proteases and C1s 
active sites, we were able to establish the substrate specificity pocket S1 site (cyan) and 
catalytic triad (slate blue) of the C1r serine protease. (B) With the published structure of C1r-
CCP2-SP, compounds were docked according to the lowest energy docking pose. All four 




compounds strongly favoring C1r-CCP2-SP over C1r-CUB1. Compounds cmp-1663 (KD, C1r = 
127 μM vs. KD, C1r-CCP2-SP = 137 μM), cmp-1696 (KD, C1r = 183 μM vs. KD, C1r-CCP2-SP = 211 μM), 
and cmp-1827 (KD, C1r = 202 μM vs. KD, C1r-CCP-SP = 213 μM) all bound with similar affinity to 
both C1r and C1r-CCP2-SP, while cmp-1611 (KD,C1r = 115μM vs. KD,C1r-CCP-SP = 694 μM) bound 
C1r-CCP2-SP with ~6-fold weaker affinity as compared to full-length C1r (Figure 12 A-H). On 
the other hand, cmp-1611, cmp-1663, cmp-1696, and cmp-1827 bound C1r-CUB1 with 28-fold, 
176-fold, 29-fold, and 9-fold lower affinity compared to full-length C1r, respectively. 
The SPR binding experiments provided evidence that the catalytic cleft, substrate 
specificity pocket S1 site, or both sites of C1r-2SP, is the preferred binding site of the four lead 
compounds. Due to the binding proximity of these compounds to the proteolytically active site of 












3.6 Enzymatic cleavage inhibition assay 
         To determine whether C1r activation is directly blocked by our lead compounds, we 
utilized pre-activated full-length C1r enzyme, C1r-CCP-2SP enzyme, or subsequent classical 
complement pathway protease C1s enzyme, in an enzyme inhibition assay that is measured by 
Figure 12. Domain mapping of dose-dependent binding of four lead compounds by SPR. 
(A-C) The four lead compounds were injected at 500 μM final compound concentration over 
immobilized full-length C1r. Dose-dependent binding response was measured using variable 
concentrations. Steady-state affinities and KD’s were calculated from the resulting data. (E-H) 
The ability of the compounds to dose-dependently bind C1r-CCP2-SP domain truncation 
mutant was assessed using identical means as full-length C1r. 
KD = 690 ± 64 µM 
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colorimetric change of Ellman's reagent (5,5'-dithiobis-(2-nitrobenzoic acid) or DTNB) marked 
by enzymatic cleavage of synthetic peptide substrate Z-Gly-Arg-SBzl. The compounds were 
utilized at a final concentration of 5 mM, (except for cmp-1663, which is insoluble at this 
concentration in reaction buffer and thus excluded) though, only cmp-1696 exhibited inhibition 
of C1r and C1r-CCP-2SP enzymes but not C1s. 
3.6 Activity of structural analogs 
Having previously identified molecularly distinct core structures, we sought to identify 
structural analogues of our lead compounds to find other dose-dependent binding and inhibitory 
compounds of C1r (Figure 13). Thirty-two additional compounds were generated from a 
structure similarity search and obtained for further testing with four analogs deriving from cmp-
1611, ten from cmp-1663, 14 from cmp-1696, and four from cmp-1827. Utilizing previously 
employed SPR binding experiments and ELISA-based assays, six of the 32 exhibited similar 
IC50’s and KD’s to the original compounds, marking the identification of six new, novel 
compounds (Figure 14). Two derived from cmp-1611, one from cmp-1663, one from cmp-1696, 




Further comparison of their core structures with those of their corresponding lead 
compounds, yielded the identification of structurally diverse common core fragments belonging 
to each group (Figure 14). In the case of cmp-1611, each active compound contains a central 4,6-
dimethylpyrimidine core fragment, while the two active cmp-1663 compounds are isomers 
differing in the position of a methyl group on a benzene ring. The active cmp-1696 analog (cmp-
1696-7) is a derivative of cmp-1696 with an additional ethylpyridine substituent, while the active 
cmp-1827 compounds all contain a central 4-methylimidazole ring. 
 
Figure 13. Predicted binding site of compounds and analogues within or near the catalytic 
cleft of C1r. The published crystal structure of the serine protease domain of C1r was utilized 
to generate the most probable docking poses of the active analogues of our four lead 
compounds within the space defined by the highlighted surface of interest (red) within the 
boxed region of the serine protease domain. The substrate specificity S1 pocket and catalytic 
triad are present within the specified area, and all compounds and their respective analogues 




Figure 14. Dose-dependent inhibition of lead compounds and their analogues. (A-C) 
Structural analogues of our lead compounds were determined using a structure similarity search 
of cmp-1611, cmp-1663, cmp-1696, and cmp- 1827. In vitro ELISA assays measured C4b 
deposition as a basis for classical complement inhibition for compounds and their analogues. 
Two cmp-1611 analogs, one cmp-1663 analogs, one cmp-1696 analog and two cmp-1827 
analogs exhibited dose-dependent binding and complement inhibition. 
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3.7 Activity of in silico docking hit fragment compounds  
In a separate and independent in silico docking experiment, Chemalytics was employed 
to identify compounds de novo from the ZINC database predicted to dock near or within the C1r-
CCP2-SP catalytic cleft through the published C1r-domain truncation crystal structure. 
Compounds were ranked based on their theoretical binding affinities and favorable binding 
poses, and from that experiment, 756 unique compounds were identified. Eighty showed 
favorable physicochemical binding properties, and twenty-one of those compounds were 
identified to share the same core fragment structures as our four compounds (Figure 15 A-B). 
This discovery provided further evidence for the binding and inhibitory qualities of the core 
















Figure 15. Structurally similar compounds derived from in silico docking experiment. An 
alternate screening method generated a list of 756 additional structurally diverse compounds 
predicted to bind C1r-CCP2-SP. (A) Of those compounds, 80 compounds exhibited favorable 
physicochemical properties for C1r-binding and inhibition. The magnified box displays four 
randomly selected compounds of the 80 to illustrate structural distinction between the screened 
compounds. In total, 21 of those were identified to have at least one of the same core fragments 
of four lead compounds. (B) Structural similarity determinations were based on these fragments 
unique to the four compounds and their respective analogues. 
 
A 




We selected the top seven compounds that shared structural similarities to our lead 
compounds from the in silico docking experiment based on favorable xLogP values (compounds 
with greater affinity for aqueous phase). Of those seven, one shared core fragments with cmp-
1611, two with cmp-1663, one with cmp-1696, two with cmp-1827, and one shared core 
fragments with cmp-1611, cmp-1663, and cmp-1696. Additionally, three compounds are already 
available on the market as drugs, and are nilotinib, lumacaftor, and edarbi. The seven compounds 
were ordered for testing and arbitrarily labelled docking hit 001 through docking hit 007 
(DH001-007).  
 
Figure 16. Structural similarity of core scaffolds within available drugs from in silico 
docking experiment. (A-C) From the seven selected compounds of the docking experiment 
that shared structural similarities with our four lead compounds, three are available on the 
market currently as drugs. Nilotinib shares core scaffolds with cmp-1611 and cmp-1827. Edarbi 
shares structural similarities with cmp-1696 and cmp-1827. Lumacaftor has a similar core 








A B C 
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These seven docking hits were resuspended to concentrations of either 10 mM, 50 mM, 
or 100 mM based on solubility in DMSO. They then underwent testing for classical complement 
inhibition in both enzymatic cleavage assays and ELISA-based in vitro assays (Figure 17). None 
of the compounds generated reproducible inhibition results under either experimental method, 
especially when compared to known nonselective serine-protease inhibitor, futhan, which 
functioned as a basis for comparison of effective dose-dependent inhibition. 
 






















Figure 17. Activity of common core fragment compounds in ELISA. Docking hits were 
tested using 500 μM final concentration against normal human serum (NHS) for inhibition of 
C4b deposition. Despite in silico docking predictions near or within the C1r-CCP2-SP 




CHAPTER 4: CHEMINFORMATICS-BASED APPROACH 
4.1 Molecular docking analysis of C1s-binding compounds 
Intervention at the C1 level can be achieved outside of C1r by targeting secondary 
protease, C1s, whose activation is also critical for initiation of the classical complement cascade, 
as its only two native substrates are C2 and C4. In a parallel approach, we used a 
cheminformatics-based approach to identify small-molecule compounds with druglike 
characteristics that are predicted to bind C1s. Using the published structure of C1s, four critical 
sites responsible for enzymatic function and activation were established. These docking sites 
were determined based on the intermolecular contacts that C1s makes within the C1 complex. 
These structure-guided determinants were identified using published C1s crystal structures, cryo-
EM, and small angle x-ray scattering studies (SAXS). The sites, i) C1q/C1s interface, ii) C1r-C1s 
interface, iii) C1s dimer interface, and iv) C1s scissile loop, were defined in Chemalytic’s 
implementation of AutoDock Vina, a program designed to computationally index druglike 
compounds and their properties from in silico libraries. Utilizing the public-access ZINC 
database, 4.27 million compounds were theoretically docked within one of the four sites (Figure 
18a). 
Due to its activity and function as a serine protease, we targeted the active site within the 
serine protease domain of C1s for therapeutic intervention by virtual screening of small-molecule 
compounds from the ZINC database. Using AutoDock Vina, compounds were screened for C1s 
docking potential (Figure 18B). In total, approximately 150,000 drug-like compounds and FDA-




      
 
Figure 18. C1s Cheminformatics workflow and in silico docking schematic using 
AutoDock Vina binding box. (A) Critical docking sites were established using C1s structure-
based design. Virtual screening of the ZINC compound database yielded compound leads that 
were prioritized and ranked based on binding energy and physicochemical properties to 
generate “hits” for in vitro validation assays. Compound hits will be expanded through 
structure-based similarity searches for additional promising compound leads. (B) Using 
published C1s crystal structure, molecular mechanisms of function, activation, and ligand 
interaction can be better understood for determination of critical target sites on the serine 
protease domain. Those sites can be defined using AutoDock Vina to virtually screen for 




The hits generated from in silico docking experiments were then prioritized based on the 
averaged calculated binding energies of the six most favorable compound conformations. Those 
with a score of 4.5 standard deviations above the average docking score were analyzed for their 
xLogP aqueous solubility values (Figure 19). The solubility of a compound in aqueous solution 
is of concern in drug development because hydrophobicity can drive toxicity as it is generally 
retained longer in the body. Additionally, insoluble compounds can damage SPR instrument 
components and give false reads 56. Using ChemMine’s hierarchical clustering software, 
compounds with high theoretical C1s-binding affinity, favorable physicochemical properties, and 





4.2 C1s-binding and inhibition properties of triaged compounds 
Fifty-two compounds were selected for in vitro validation using the SPR, as previously 
described for C1r. Selected compounds were commercially synthesized (ChemDiv) and obtained 
in larger quantities. Compounds were resuspended in DMSO to a stock concentration of 100 mM 
for use in SPR, they were further diluted to a concentration of 500 µM and injected over full-
Figure 19. C1s binding box screened against ~150,000 drug-like compounds and FDA-
approved small-molecule drugs from the ZINC database. Computationally-derived binding 
energies were averaged and prioritized. Compounds scoring 4.5 standard deviations above the 
average docking score were selected for further screening (green box). xLogP values were 




length C1s immobilized on an SPR sensorchip to assess binding. Compounds that exhibited C1s 
binding characteristics were injected over recombinantly expressed C1s-CCP2-SP domain 
truncation over varying concentrations ranging from 7.8 to 500 µM to measure the dose 
response. In total, 28 compounds have been assessed and ranked based on binding affinity. From 
the prioritized compounds, compound B-5 emerged as having the greatest, reproducible binding 
affinity to C1s with a KD of 5 µM to that of 38 µM in control compound, futhan. B-5 was tested 
for dose-dependent inhibition of the classical pathway in two-fold multivariate concentrations by 
measurement of C4b deposition in ELISA-based classical pathway inhibition assays and showed 














As of yet, no small-molecule compounds from our study have been identified as potent 
C1s inhibitors. Despite this, C1s remains a promising therapeutic target for ameliorating classical 
A B-5 
KD = 5 µM 
B Futhan 
KD = 38 µM 
Figure 20. Dose-dependent binding of C1s-CCP2-SP by compound B-5 versus 
promiscuous serine protease inhibitor, futhan, does not yield inhibition of the classical 
pathway. (A-B) Compound B-5 and futhan were injected over immobilized C1s-CCP2-SP 
domain truncation and assessed for dose-dependent binding. B-5 exhibited similar binding 
affinity as the control, futhan, KD = 5 µM and KD = 38 µM, respectively. (C) Despite its binding 
capabilities, B-5 did not inhibit classical pathway activation in ELISA-based inhibition assays. 






pathway-mediated diseases. Increased screening and evaluation of potential hit compounds is 
needed for future studies. We plan on expanding our compound list and continuing to assess 
promising leads generated by in silico computational docking via in vitro biochemical and 
functional validation assays.
 
CHAPTER 5: CRYSTALLOGRAPHY 
5.1 C1r-2SP WT 
To obtain empirical binding data for our small-molecule compounds in complex with 
C1r, we strove to produce high-resolution x-ray diffraction data from co-crystallization. In order 
to attain a suitable protein concentration for obtaining crystal structures, we produced 3 mg/mL 
of C1r-CCP2-SP domain truncation (after correcting for the extinction coefficient of 1.6). We 
achieved recombinant expression of C1r-CCP2-SP using BL21 E. coli and purified the protein 
using gel filtration on FPLC. After having produced sufficient concentration of protein, we 
concentrated our samples down to the target concentration of 3 mg/mL using 3K MWCO 
microcentrifuge spin filters and buffer exchanged the protein into 20 mM HBS solution. Using 
the wide range of crystal conditions provided by Hampton Crystal and Index Screens, we 
transferred both C1r-truncation and 5 mM concentration of target compound into sitting drop 
trays using the crystal griffon instrument for co-crystallization through compound soak. 
In doing so, two conditions provided working crystals in less than 48 hours after transfer 
to the sitting drop trays. Select crystals were cryoprotected and sent to Argonne National Labs 
for x-ray diffraction data collection using beamline 22-ID or 22-BM of the Advanced Photon 
Source. X-ray diffraction data were collected by shooting the crystal with an x-ray laser over 
180° of the crystal surfaces. Once x-ray diffraction data were collected, we utilized the published 
2.8Å resolution crystal structures of C1r-CCP2-SP (1GPZ) to solve our structure of 1.8Å 
resolution by accounting for rotamer analyses, bond constraints, and electron densities, which 
indicated the presence or absence of structural components, among others using WinCoot for 
crystallographic structural imaging and manipulation in conjunction with Phenix crystallographic 
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molecular structure determination software. After completion of the solved crystal structure 
using Phenix, an unexplained electron density remained within the substrate specificity S1 site of 
the serine protease domain. Though we had anticipated that our compounds would dock within 
this site, further analysis revealed that rather than binding our compound in complex with C1r, 
the flexible rotamer of arginine-463 of the serine protease domain blocked availability of the 
active site (Figure 21A). When in tight crystal complex with other C1r-CCP2-SP proteins within 
the asymmetric unit, the arginine-463 rotamer invariably folded within the S1 site, blocking any 
compound docking. Trypsin-like serine proteases, such as C1r and C1s, are often characterized 
by a negatively charged aspartate located at the base of the S1 pocket 9. This negative charge 
drives specificity for cleavage of positively charged amino acids. In tight complex with other 
C1r-CCP2-SP proteins, it is likely that positively charged arginine-463 is driven to the S1 site by 
the negatively charged aspartate. To overcome that unforeseen obstacle, we decided to create a 
C1r-CCP2-SP domain truncation mutant in which the arginine is replaced with a glutamine to 












5.2 C1r-2SP R463Q 
To address the obstacle of the arginine-463 side chain of neighboring C1r-CCP2-SP from 
blocking the S1 site of C1r, we created a C1r-CCP2-SP domain truncation mutant in which the 
arginine was substituted with a glutamine. This protein structure was recombinantly expressed in 








Figure 21. Mutating arginine-463 for glutamate allows for accessibility of the S1 site in 
C1r-CCP2-SP domain truncation crystal. (A) The arginine side chain (yellow residue) of 
the serine protease domain of neighboring C1r folds into the S1 site (purple) of WT C1r-CCP2-
SP (gray). The figure depicts a portion of neighboring C1r-2SP protein (green, cyan, and yellow 
residues) interacting with C1r-CCP2-SP. When in tight crystal formation, this action obstructs 
accessibility to the S1 or catalytic site (marine blue) by small-molecule compounds. (B) To 




protein was transferred into 20 mM HBS and soaked with our four lead compounds, yielding two 
successful crystal conditions containing three crystal structures that provided 1.8 Å high-
resolution x-ray diffraction data. Using published C1r-CCP2-SP R463Q mutant PDB model 
(1GPZ), with Wincoot and Phenix software, all three structures were solved, though none 





Figure 22. C1r-CCP2-SP domain truncation mutant suspended in crystal screen reagent 
drop and its solved molecular crystal structure. (A) C1r-CCP2-SP R463Q mutants were 
crystallized in 0.2 M sodium acetate trihydrate, 0.1 M Tris hydrochloride pH 8.5,  and 30% w/v 
polyethylene glycol 4,000. These crystals produce a birefringent effect upon interaction with 
polarized light due to two distinct indices of refraction. (B) Electron density maps generated by 
C1r PDB model 1GPZ in Phenix and Wincoot allowed for molecular structural determination 
of our crystals. Upon completion of the solved structure, the electron density maps did not 









Data collection and refinement C1r-CCP2-SP(307-705) 
Data collection  
  Space group P 2 21 21 
  Cell dimensions  
    a, b, c, Å 37.87, 91.41, 91.95 
    α, β, γ, ° 90.00, 90.00, 90.00 
  Resolution, Å 41.1 – 1.70 (1.76 – 1.70) 
  Rpim
a 0.078 (0.383) 
  I/σIb 18.14 (2.14) 
  Completeness, % 99.0 (99.6) 
  Redundancy 5.7 (5.3) 
Refinement  
  Resolution, Å 41.0 – 1.70 
  No. reflections 35,680 
  Rwork/Rfree
c 19.58 / 21.99 
  No. non-hydrogen atoms 2,732 
    Protein 2,476 
    Water 256 
  B-factors  
    Protein 23.77 
    Water 31.90 
  RMSD d  
    Bond lengths, Å 0.010 
    Bond angles, ° 1.123 
Table 1. C1r-CCP2-SP R463Q data collection and refinement statistics (molecular 
replacement). Values in parentheses are represent the highest-resolution shell. The 
crystal structure of C1r-CCP2-SP R463Q was solved using Phaser-MR using the 
previously published structure of C1r-CCP2-SP (1GPZ). The final model was obtained 
using WinCoot-CCP4 and refinement in Phenix 1.16-3549. Models were validated using 
Molprobity and the structural representations were prepared using PyMOL.  
a Rpim is the measure of precision of the averaged intensities and amplitudes.  
b I/σI is the precision indicator for the individual observations, where σ is error 
propagation. 
c 
R = ∑h| Fo(h) − Fc(h) | / ∑h| Fo |. Rwork and Rfree were calculated from the working and test 
reflection sets, respectively. The test set constituted 10% of the total reflections not used in 
refinement. 
d
 RMSD is the root-mean-square deviation of atomic particles that accounts for the measure of 





 Another issue arising from the crystallization of C1r-CCP2-SP was that C1r was 
autoactivating, even in the presence of inhibitor. In order to disrupt autoactivation of C1r, we 
mutated serine-654 of the catalytic triad to an alanine to stabilize the zymogen form of C1r-
CCP2-SP. C1r-CCP2-SP S654A mutant was recombinantly expressed by BL21 E. coli and 
crystallized in solution with inhibitor. X-ray diffraction data obtained from the S654A mutant 
crystals showed that despite mutation of a key residue within the active site, C1r had undergone 
activation. We speculate that bacterial proteases from E. coli activate C1r during synthesis or 
purification of C1r-2SP. 
5.4 C1r-2SP TEV-activatable clone 
 To control activation of C1r, we designed clones that can only be activated by tobacco 
etch virus (TEV) directed to a TEV-specific DNA sequence insert in transformed pT7HMT 
plasmid into DH5α E. coli. To achieve this end, we mutated the conserved RQRIIG residues of 
wild-type human C1r-CCP2-SP to the TEV-activatable sequence, ENLYFQ (Figure 23). We 
hypothesize that this transformation will inhibit C1r activation and allow for binding by an 
inhibitor to the active site of C1r. C1r-TEV-activatable mutants were recombinantly expressed 












Figure 23. Site-directed mutagenesis to control C1r activation. The S3-S5’ sites denote 
specific amino acid residues that comprise the molecular determinants for C1r-substrate 
specificity. The black arrows indicate the disulfide bridge between arginine and isoleucine that 
must be cleaved in order to achieve C1r activation. The amino acids in bold represent those 
present in WT C1r-CCP2-SP, whereas those in red have been exchanged for E. coli-optimized 
tobacco etch virus (TEV) sequences. By withholding the TEV protease, C1r is expected to 
remain in its zymogen form. 
 
CHAPTER 6: DISCUSSION 
 Advancements in scientific research and medical technologies that are rapidly expanding 
our understanding of molecular disease mechanisms and triggers comes at no better time than 
now as our US population is aging. Within the next 40 years, the number of Americans aged 65 
and older will more than double, placing increased weight on developing therapeutics directed 
towards age-related degenerative disorders. One such example is Alzheimer’s disease, which is 
significantly burdening our aging population, as well as government resources and healthcare 
system. It is currently the sixth leading cause of death in the United States, and its impact is only 
expected to escalate 71. Neurodegenerative inflammatory diseases, such as Alzheimer’s disease, 
have complex pathogenic mechanisms, and complement’s involvement in exacerbating and/or 
driving pathogenesis is becoming increasingly evident. Given the complexities of each disease, 
there will obviously be no “cure-all” drug and the need for specific disease-tailored therapeutics, 
especially in the anticomplement drug field, serves as the catalyst for many studies such as this. 
The successes of complement-directed drugs, eculizumab and C1-INH, on the treatment 
of a growing list of diseases has put the spotlight on anticomplement therapeutics. Currently, 
there are over 40 different anti-complement drugs in various stages of clinical development 49. 
The majority of these drugs focus on targeting the complement pathway convertases. However, 
complement therapeutics directed at the C3 and C5 level overlook pathway-specific disease-
initiation mechanisms in a wide spectrum of complement-mediated diseases, such as 
Alzheimer’s disease. Moreover, targeting a specific activation pathway presents the capacity for 
continued immune surveillance by the remaining intact pathways. 
Despite increased interest in the treatment of complement-mediated disorders, there 
remains a void in drugs targeting the initiating proteases of the classical and lectin pathways. The 
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classical complement pathway has been implicated in a growing disease inventory due to its 
diverse assortment of pathway activators. Historically, complement’s oldest known role was as a 
support function in antibody-mediated bacterial clearance. Indeed, the classical pathway is 
frequently activated by immune complex recognition and binding by C1q to the surface 
membrane of foreign invaders, cellular debris, and/or host cells, such is the case with heparin-
induced thrombocytopenia, neuromyelitis optica, bullous pemphigoid, and ischemia-reperfusion 
organ injuries 20,72–74. However, classical pathway activation can occur by C1q attachment to 
over 100 diverse ligand activators, such as amyloid-β plaques and neurofibrillary tangles, as 
implicated in Alzheimer’s disease 75. 
At present, there is a paucity of classical pathway-specific drugs, with only three 
currently available on the market. Recombinant and native preparations of C1-INH 
(Cinryze/Berinert/Ruconest) have been approved by the FDA for treatment of hereditary 
angioedema, and they are also now being evaluated more broadly for treatment classical and 
lectin pathway-mediated pathologies, such as acute antibody-mediated rejection following 
allogeneic organ transplantation and septicemia/SIRS 28. Anti-C1q antibody ANX005 (Annexon 
Biosciences) and anti-C1s antibody TNT009/BIV009 (True North Therapeutics) are presently in 
phase I and phase III clinical trials for treatment of Guillain Barré syndrome and cold agglutinin 
disease, respectively 49. Inhibition of the classical pathway cascade through C1-directed drugs is 
showing promise for the treatment of a broad range of classical pathway-mediated diseases in the 
current clinical landscape, making the pathway initiating serine proteases, C1r and C1s, 
favorable therapeutic targets. 
Still, there are many challenges facing the development of anticomplement drugs, such as 
dosage, tissue penetrance, and specificity. Antibody development against complement 
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components is the most prevalent intervention strategy, but its use has highlighted obstacles in 
complement therapeutics. Due to the abundance of complement proteins in plasma and the high 
rate of turnover, delivering sufficient concentrations of such a large inhibitor as an antibody is 
problematic, with breakthrough thrombosis a possible consequence, as reported with eculizumab 
treatment 76. Small-molecule inhibitors can overcome this pitfall through oral bioavailability, 
which is not possible with anti-complement antibodies. Repeat dosing by orally bioavailable 
small molecules allows for treatment of chronic conditions 50. Small-molecule inhibitors can also 
be rapidly cleared from the body once dosing ceases for full restoration of complement activity 
for immune function. Small-molecule drugs also have an advantage over biologics by being able 
to diffuse to sites of tissue damage and inflammation. This limitation of biologics is exacerbated 
in organs protected by tight membrane barriers, such as the blood-brain-barrier 77. In immune 
privileged disease sites, such as the brain or eye in neurodegenerative and ocular diseases, barrier 
dysfunction is often observed resulting in leaky cell junctions, easing tissue penetrance by small-
molecule inhibitors 78. Lack of specificity with small-molecules can be overcome with structure-
based drug design where a full appreciation of the binding modes, protein interactions, and 
specific surface features of the target complement protein can allow for optimization of 
selectivity in small-molecules 79. Major breakthroughs in small-molecule drug development have 
recently emerged with the development of small-molecule antagonists against factor B and factor 
D of the alternative pathway 55,66. The development of orally bioavailable small-molecule 
inhibitors has the added benefits of increasing patient compliance and lowering costs associated 
with these therapies. 
In our study, we aimed to target the initiating proteases, C1r and C1s, of the classical 
pathway of complement to halt pathway activation at the level of C1. Classical pathway 
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initiation occurs upon C1q attachment to a target site, which sets off the autoactivation of the 
chymotrypsin-like serine protease, C1r. C1r then functions to proteolytically cleave the 
subsequent C1 protease, C1s. The activation of these two proteases kicks off the classical 
pathway cascade, rendering C1r and C1s the most upstream enzymatic targets of the pathway. 
Through the identification and development of small-molecule inhibitors of these proteases, we 
hope to specifically inhibit activation of the classical pathway and expand the anticomplement-
therapeutic toolkit. 
To develop small-molecule inhibitors, we employed two structure-based, orthogonal 
approaches to compound screening. Using fragment-based drug discovery, we screened 
compound libraries for fragments that can be optimized for highly competitive binding 
interactions with C1r and high levels of specificity. Our fragment search and screening produced 
four structurally distinct small-molecule inhibitors of C1r: cmp-1611, cmp-1663, cmp-1696, and 
cmp-1827 that all bind near or within the catalytic cleft of the serine protease domain. 
Optimization strategies to augment identified fragments into compound leads has seen great 
success in the development of potent, drug-like small-molecule inhibitors through the process of 
fragment linking, growing, and/or merging, all of which rely on careful structure-based design 80. 
The success of factor D small-molecule inhibitor development is a prime example of the 
potential of small-molecules in enzymatic complement inhibition 55. In a parallel approach, we 
utilized cheminformatics to virtually screen compound libraries for drug-like compounds 
predicted to bind within specific target sites on the C1s serine protease. Compound B-5, derived 
from screening drug-like compounds of the “Leads Now” subset of the ZINC database, showed 
promise for its ability to dose-dependently bind C1s. Yet, its binding affinity was not 
representative of its ability to block C1s activity. As of yet, no inhibitory compounds have been 
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identified for C1s, necessitating continued efforts in the evaluation of compound leads. High-
resolution crystal structures of our recombinantly expressed and renatured C1r/C1s domain 
truncations and domain mutants will significantly advance and promote the success of this study. 
The molecular nuances of protein-protein interactions and critical surface structures from our 
crystallographic efforts were extremely helpful for guiding the development of our small-
molecule antagonists.  
Our work has produced four structurally distinct, small-molecule compounds that bind 
the active site of the initiator protease of the classical pathway of complement, C1r. Each 
compound will, in a dose-dependent manner, block C1r activation, thereby preventing classical 
pathway activation. In addition, each compound has favorable physicochemical properties for 
independent or combinatorial optimization strategies. It is our hope that continued efforts in co-
crystallization and optimization of these compounds will allow for the advancement of highly 
specific, high-affinity small-molecule inhibitors of C1r and C1s. The development of this type of 
inhibitor targeting the activation of C1 could provide valuable and novel insights for the 
mechanisms of C1 inhibition, as well as provide potential treatment options for diseases 
mediated by the aberrant activation of the classical pathway of the complement system.
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Surface plasmon resonance  
Surface plasmon resonance (SPR) is an instrument used to quantify and analyze 
molecular binding interactions between an immobilized protein and a solubilized, mobile 
analyte. This is achieved by measuring the change in reflected intensity of a light beam upon 
interaction with the metal film upon which the ligand is immobilized. SPR utilizes the 
differential refractive indices of a prism, through which polarized light is projected, and the 
metal film (typically gold or silver) on the surface of the sensor chip 81. 
The protein of interest is immobilized onto a sensor chip by amine-coupling reaction. The 
CM5 sensor chip is inserted into the Biacore T200 and N-Hydroxysuccinimide (NHS)/ N-ethyl-
N’-(dimethylaminopropyl) (EDC) is injected over the surface to activate the chip by 
modification of carboxymethyl groups to NHS esters 82. The activation of the chip surface is 
recorded as a baseline and the ligand is then injected over the chip. The N-terminus and ε-amino 
groups of lysine residues on the ligand covalently bind the sensor surface as the NHS esters of 
the chip react with the amino groups of the ligand. Unbound/electrostatically bound ligand and 
unreacted NHS-esters are eluted and deactivated by ethanolamine pH 8.5 and 10 mM NaOH 81. 
Varying concentrations of the analyte, as well as a blank, are then injected over the chip 
surface with immobilized ligand over multiple cycles. Polarized light travels through the glass 
prism and is focused onto a particular point on the metal film of the sensor surface at a set 
resonance angle 82. At the critical angle, all out-going reflected light is reflected internally (total 
internal reflection). With total internal reflection, the light is absorbed and excites the electrons 
that exist at the interface between the metal surface and prism and converts them to surface 
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plasmons, which is the particle name of the electron density wave 82. This conversion creates a 
dip or gap in the intensity of the reflected light. During a binding event between the analyte and 
ligand, there is an angular shift in position from the original dip and the dip that occurs during 
molecular binding due to the conformational change in the reactants bound to the chip surface 81.  
The binding of reactants on the chip surface also alters the refractive index, which is 
measured by the change in the resonance angle. The change in refractive index is proportional to 
the concentration of immobilized ligand, converted into arbitrary resonance units (RU) 81. During 
a binding event, the RU increases, and after a predetermined period of time, buffer is injected 
over the chip to dissociate the analyte-ligand complex, thereby dropping the RU. This angular 
shift versus time allows for quantification of binding kinetics between the target ligand and 
analyte over varying concentrations, yielding dose-dependent binding kinetics 81. The maximal 
response (Rmax) is calculated for the immobilized ligand by assuming a binding event of 1:1 with 
the analyte 82. 
The interaction between the analyte and ligand is graphically represented by the 
association event, steady state, and the dissociation event over time with no changes to the 
molecular properties of either reactant 81. With a high dissociation rate (<10-1), steady state 
experiments are used to calculate the equilibrium dissociation constant by dividing the 
dissociation rate by the association rate. Multi-cycle kinetics can also be used to define the 
interactions between reactants by injecting the analyte over the chip surface in separate cycles 









Complement inhibition assays  
Complement inhibition in this study was measured using a series of assays that looked at 
classical complement pathway inhibition via downstream complement product deposition, direct 
inhibition of the initiating proteases, C1r or C1s on a peptide substrate, or complement-mediated 
hemolysis of sheep red blood cells. Classical pathway inhibition measured by C4b deposition 
utilizes an enzyme-linked immunosorbent assay (ELISA) to assess the presence of proteins by 
antibodies. Because complement is normally found circulating in normal human serum at 
relatively high concentrations, complement fixation products must be bound and immobilized to 
quantify deposition and, ultimately, complement activation.  
To facilitate complement fixation, IgM antibody is immobilized on a high-binding, 96-
well plate. The remaining open surfaces of the wells are then blocked with 1% bovine serum 
Appendix Figure 1. SPR schematic of instrument mechanisms and enzyme kinetic 
analysis. (A) Molecular binding interactions between protein and analyte is measured by the 
change in the reflected intensity of a light beam upon interaction with the metal film upon 
which the ligand is immobilized. Utilizing the differential refractive indices of a prism, 
through which polarized light is projected, and the metal film (typically gold or silver) on the 
surface of the sensor chip. Polarized light is focused onto the chip surface, and during a 
molecule binding event, a change in refractive index is marked by an angular shift in the 
intensity of reflected light 80. (B) The interaction between the analyte and ligand is graphically 
represented by the association event, steady state, dissociation event and subsequent 




albumin to prevent non-specific binding of complement proteins or antibody. When 2% normal 
human serum is added to the microtiter wells, the pentameric structure of IgM is targeted by 
recognition molecule, C1q, within the C1 complex. A potent and specific inhibitor of C1 
proteases simultaneously dispensed into solution would block the subsequent activation of bound 
C1, thereby halting the proteolytic cascade from forward progression. However, if C1 activation 
is not impeded, C1r autoactivates and cleaves zymogen C1s. C1s cleaves C4 into a trimer and C2 
into its dimer subunits. While C4a, C4c, and C2a are released into fluid-phase, C4b and C2b 
remain bound together at the plate surface as C3-convertase.  
While downstream complement deposition products can also be measured, isolation of 
C4b by mouse anti-C4b hybrid antibody eliminates alternative pathway from consideration, so 
that only classical complement activation (and/or lectin pathway) is measured. With C4b and 
murine anti-C4 hybrid antibody in complex at the plate surface, secondary anti-mouse goat 
antibody conjugated to horseradish peroxidase (HRP) is added to bind the existing immune 
complex and amplify signal detection of C4b by 3,3′,5,5′-Tetramethylbenzidine (TMB), the 
colorimetric reagent used for visualization of target proteins. To prevent undesirable continued 
reaction progression and increased background signal, sulfuric acid is added as the stop reagent, 
changing to solution from blue to yellow.  
Differential optical density read by spectrophotometer microplate reader at 450 nm 
represents varying degrees of complement activation and thus complement inactivation by 
compound inhibitor. By serially diluting the inhibitor concentration, dose-dependent inhibition 
can be assessed. Serving as controls for the assay are two rows dedicated to either 100% 
complement activation, in which there is no inhibitor, or 0% complement activation, in which 
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there is neither normal human serum nor inhibitor but only classical pathway-specific assay 
buffer.  
 
The second method by which to quantify C1r or C1s inactivation is by inhibition of 
enzyme-mediated cleavage of a peptide substrate specific for that protease by the inhibitory 
compound under investigation. In our study, we found that peptide, Z-Gly-Arg-SBzl, provided 
the optimal substrate for C1 protease to act upon. 
In a 96-well conical plate, 500 µM final concentration of enzyme was added concurrently 
with 50 mM Tris buffer pH 8.0, and 500 µM inhibitor to allow for inhibitor-enzyme complex 
Appendix Figure 2. ELISA-based assay measuring complement activity through 
component fixation. IgM is immobilized onto a high-binding plate surface and blocked from 
non-specific binding. Normal human serum containing complement is introduced to the plate 
with the presence of an inhibitor. If complement is active, C1q will bind IgM and activate the 
CP. Antibody against complement fixation products is introduced and a secondary HRP-
conjugated antibody is added. With the presentation of TMB into solution, the presence and 
concentration of complement deposition fragments is marked by a colorimetric change that can 
be visualized and quantified by spectrophotometer. 
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formation. Separately, and in their own reservoir, peptide and Ellman's reagent (5,5'-dithiobis-(2-
nitrobenzoic acid) or DTNB) are mixed. DTNB is a stoichiometric measure yielding colorimetric 
changes during cleavage events measured by OD detection by spectrophotometer at 412 nm. The 
peptide-DTNB mixture is then added to the enzyme-inhibitor solution, providing rapid color 
change from the reaction of DTNB to substrate cleavage. Greater absorbance values equate to 
lesser C1 protease inhibition by the compound. To determine maximal signal, one row is 
designated as the positive control without any inhibitor present in solution. The negative control 
row contains no enzyme to account for background noise. 
X-Ray Crystallography 
X-ray crystallography utilizes the diffraction patterns of a crystal sample to yield a three-
dimensional molecular structure for making structural determinations of proteins or biological 
macromolecules. Protein crystallography relies on the high quality and high concentration of 
homogenous, soluble protein. Crystals are grown from protein solutions containing a minimum 
protein concentration of 2 mg/mL that are induced to slowly precipitate out of solution in the 
form of a crystal under given crystallization conditions 83. These conditions can be obtained 
through commercially available “crystal screen” packages containing 50 solutions of differing 
precipitant, buffer, pH, and salt 83. The leading conditions in our study for the crystallization of 
wild-type C1r-2SP were 0.2 M sodium acetate trihydrate, 0.1 M Tris hydrochloride pH 8.5,  and 
30% w/v polyethylene glycol 4,000 in one and the second containing 0.2 M magnesium chloride 
hexahydrate, 0.1 M Tris hydrochloride pH 8.5, 30% w/v polyethylene glycol 4,000.  
Crystallization of the protein occurs through vapor diffusion of the 2 µL protein drop 
solution exchanged with the 50 µL crystallization solution. There are two techniques for 
establishing vapor diffusion. One method is manually introducing a “hanging drop” of the 
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sample suspended from a glass coverslip over a reservoir of the crystallization condition while 
the other method is mechanically establishing vapor diffusion through a “sitting drop,” which 
utilizes a Crystal Gryphon instrument that dispenses the proteins into 96-channel crystal plates 
containing the crystallization condition 83. To co-crystallize a compound in complex with the 
protein, small volumes of compound solution are added to the protein sample prior to vapor 
diffusion. 
Crystal growth can take days or weeks at room temperature, but once crystals are 
obtained, they are introduced into a cryoprotectant buffer so that they may be collected and 
stored in liquid nitrogen to prevent degradation. In our study, our proteins are then sent to the 
Southeast Regional Collaborative Access Team (SER-CAT) located at the Advanced Photon 
Source at the Argonne National Laboratory for diffraction analysis.  
When the crystals are ready for analysis of their x-ray diffraction behavior, they are  
remotely and mechanically mounted within a rotating spindle and adjusted for proper alignment 
with the x-ray beam using what is called a goniometer head. The x-rays are generated by 
accelerating electrons in a synchrotron storage ring and the x-rays focused into a beam. The 
diameter of the incident beam, as well as alignment of the crystal must be carefully adjusted to 
ensure proper exposure and prevent radiation damage 83.  
The crystal rotates within the spindle perpendicularly to the incident beam to provide the 
maximum amount of diffraction data. After exposure, diffraction spots are collected on an 
imaging plate revealing a digitized image. The diffraction spots are resolved based on the 
distance from the crystal to the detector with the highest resolution accounting for the edge of the 
detection. The diffraction image becomes strongest at lower resolutions, with a resolution of 3 Å 
sufficient for detecting amino acid side chains in an electron density map. The resolution of the 
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image is dictated by how well-ordered the molecular subunit is. Within the crystal, the unit cell is 
defined as the smallest repeating unit that makes up the crystal with dimensions given by three 
lengths and angles. The dimensions of the unit cells are proportional to the number of diffraction 
spots for a given unit area. The space group of the crystal is given by the symmetry of the 
diffraction pattern, which is defined by the configuration and packing of the molecules within the 
crystal lattice. The more symmetrical a crystal structure, the more ordered the diffraction spots 
appear in the image 83.  
Computer programs with well-established algorithms for making structural 
determinations are employed to resolve the unit cell dimensions and orientation, measure the 
intensity of diffraction spots, and normalize spot intensity using a scale factor to relate all the 
information within the data set. Given the availability of published models of related protein 
structures, molecular replacement is utilized to reconstruct amino acid sequences within the 
protein. Combining the “borrowed” model and diffraction data produces electron density maps 
that account for the location and bond angles of amino acid sequences of the protein. The crystal 
structure must undergo several rounds of model building and refinement to establish the 
structural molecular nuances of a given protein.  The quality of the protein model is calculated 
from the reflection data and given by an R-factor 83. The lower the R-value, the closer the fit is to 
“perfect.” In general, a random set of atoms produces an R-value of approximately 0.63, whereas 










Appendix Figure 3. Protein x-ray crystallography schematic. An x-ray beam generated from 
the synchrotron storage ring is directed at the protein crystal that has been properly aligned within 
its rotating spindle using the goniometer head. The resultant diffraction pattern is visualized on 
an imaging plate to yield protein structural determinations. 
 
 
 
